Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
← catalyst calendarSponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
2,202actual
Sites
279
Countries
Argentina, Australia, Belgium +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-30 | actual | When the study began enrolling |
| Primary completion | 2025-05-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-06 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gout
- Hyperuricemia
- Gout Flare
- Tophi
Interventions
- Drug: Tigulixostat — also filed as LC350189
- Drug: Allopurinol
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFThe proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6
measured Up to Month 6
Publications
- PMID 39929260 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed